According to filings with the U.S. Securities and Exchange Commission, Diligent Pharma is raising $9,250,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Patricia Leuchten played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Diligent Pharma
At Diligent we connect clinical research sponsors, CROs, technology and service providers – quickly, efficiently and at very low risk. This can reduce the time taken to start clinical trials by up to 70 days. The cloud-based Diligent Qualification Platform holds comprehensive Request For Information (RFI) details for industry suppliers around the world, as well as Vendor Qualification Assessments (VQAs) audited against latest industry standards. This makes it easy for trial sponsors to identify and qualify relevant potential suppliers – much more quickly than by using traditional methods. Its also a great timesaver for industry suppliers as it cuts the number of RFIs to be completed and VQAs to host, while providers maintain 100% control over who sees their company information. With the Diligent Qualification Platform, industry vendors are more visible and easily accessible to organizations actively searching for partners to conduct clinical research. Meanwhile trial sponsors can take advantage of the most recent technologies on the market with an objective selection process based on verified and up to date supplier details.

To learn more about Diligent Pharma, visit http://www.DiligentPharma.com/

Contact:
Patricia Leuchten, Chief Executive Officer
609-610-2815

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.